Literature DB >> 17975013

p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death.

Ondrej Krejci1, Mark Wunderlich, Hartmut Geiger, Fu-Sheng Chou, David Schleimer, Michael Jansen, Paul R Andreassen, James C Mulloy.   

Abstract

Chromosomal translocation (8;21) is present in 10% to 15% of patients with acute myeloid leukemia. Expression of the AML1-ETO (AE) fusion protein alone is not sufficient to induce leukemia, but the nature of the additional genetic alterations is unknown. It is unclear whether AE facilitates acquisition of these cooperating events. We show that AE down-regulates genes involved in multiple DNA repair pathways, potentially through a mechanism involving direct binding at promoter elements, and increases the mutation frequency in vivo. AE cells display increased DNA damage in vitro and have an activated p53 pathway. This results in increased basal apoptosis and enhanced sensitivity to DNA damaging agents. Intriguingly, microarray data indicate that t(8;21) patient samples exhibit decreased expression of DNA repair genes and increased expression of p53 response genes compared with other acute myeloid leukemia (AML) patient samples. Inhibition of the p53 pathway by RNAi increases the resistance of AE cells to DNA damage. We thus speculate that AML1-ETO may facilitate accumulation of genetic alterations by suppressing endogenous DNA repair. It is possible that the superior outcome of t(8;21) patients is partly due to an activated p53 pathway, and that loss of the p53 response pathway is associated with disease progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975013      PMCID: PMC2234055          DOI: 10.1182/blood-2007-06-093682

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults.

Authors:  D E Banker; J Radich; A Becker; K Kerkof; T Norwood; C Willman; F R Appelbaum
Journal:  Clin Cancer Res       Date:  1998-12       Impact factor: 12.531

2.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

Authors:  T Okuda; Z Cai; S Yang; N Lenny; C J Lyu; J M van Deursen; H Harada; J R Downing
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

3.  Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO.

Authors:  M Y Ahn; G Huang; S C Bae; H J Wee; W Y Kim; Y Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.

Authors:  E P Rogakou; D R Pilch; A H Orr; V S Ivanova; W M Bonner
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

Review 5.  Transgenic mouse models for studying mutations in vivo: applications in aging research.

Authors:  J Vijg; M E Dollé; H J Martus; M E Boerrigter
Journal:  Mech Ageing Dev       Date:  1997-12-30       Impact factor: 5.432

Review 6.  Tumor-suppressor p53: implications for tumor development and prognosis.

Authors:  D G Kirsch; M B Kastan
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

Review 7.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

8.  The AML1/ETO fusion protein activates transcription of BCL-2.

Authors:  L Klampfer; J Zhang; A O Zelenetz; H Uchida; S D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

9.  Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.

Authors:  Lars Bullinger; Frank G Rücker; Stephan Kurz; Juan Du; Claudia Scholl; Sandrine Sander; Andrea Corbacioglu; Claudio Lottaz; Jürgen Krauter; Stefan Fröhling; Arnold Ganser; Richard F Schlenk; Konstanze Döhner; Jonathan R Pollack; Hartmut Döhner
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

10.  Mammalian base excision repair by DNA polymerases delta and epsilon.

Authors:  M Stucki; B Pascucci; E Parlanti; P Fortini; S H Wilson; U Hübscher; E Dogliotti
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

View more
  47 in total

Review 1.  Aging of hematopoietic stem cells: DNA damage and mutations?

Authors:  Bettina M Moehrle; Hartmut Geiger
Journal:  Exp Hematol       Date:  2016-07-08       Impact factor: 3.084

2.  N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene.

Authors:  Fu-Sheng Chou; Mark Wunderlich; Andrea Griesinger; James C Mulloy
Journal:  Blood       Date:  2011-01-03       Impact factor: 22.113

3.  Splicing factor DHX15 affects tp53 and mdm2 expression via alternate splicing and promoter usage.

Authors:  John McElderry; Blake Carrington; Kevin Bishop; Erika Kim; Wuhong Pei; Zelin Chen; Ramanagouda Ramanagoudr-Bhojappa; Anupam Prakash; Shawn M Burgess; P Paul Liu; Raman Sood
Journal:  Hum Mol Genet       Date:  2019-12-15       Impact factor: 6.150

4.  ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Authors:  Hans-Peter Kantner; Wolfgang Warsch; Alessio Delogu; Eva Bauer; Harald Esterbauer; Emilio Casanova; Veronika Sexl; Dagmar Stoiber
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

5.  RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells.

Authors:  Takahiro Suzuki; Yuri Shimizu; Erina Furuhata; Shiori Maeda; Mami Kishima; Hajime Nishimura; Saaya Enomoto; Yoshihide Hayashizaki; Harukazu Suzuki
Journal:  Blood Adv       Date:  2017-09-06

Review 6.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

7.  Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.

Authors:  John Anto Pulikkan; Dmitri Madera; Liting Xue; Paul Bradley; Sean Francis Landrette; Ya-Huei Kuo; Saman Abbas; Lihua Julie Zhu; Peter Valk; Lucio Hernán Castilla
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

8.  In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Authors:  Anmaar M Abdul-Nabi; Enas R Yassin; Nobish Varghese; Hrishikesh Deshmukh; Nabeel R Yaseen
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

9.  Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Authors:  Kevin A Link; Shan Lin; Mahesh Shrestha; Melissa Bowman; Mark Wunderlich; Clara D Bloomfield; Gang Huang; James C Mulloy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

10.  Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.

Authors:  Xiaoyi Chen; Jason Clark; Mark Wunderlich; Cuiqing Fan; Ashley Davis; Song Chen; Jun-Lin Guan; James C Mulloy; Ashish Kumar; Yi Zheng
Journal:  Autophagy       Date:  2017-02-15       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.